US-CONGRESS HR1266: Combating Illicit Xylazine Act
The House Judiciary Committee voted 48-0 to advance HR1266, the Combating Illicit Xylazine Act, which would place xylazine in Schedule III of the Controlled Substances Act and require registration, recordkeeping, and reporting for all handlers.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmacies, wholesalers, and other entities that handle xylazine, including independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the provided text; the bill is still in the legislative process.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill, if enacted, would add xylazine to Schedule III, imposing DEA registration, recordkeeping, and reporting requirements on all handlers, and would direct the DEA to establish a process to address xylazine-related overdose deaths.
Who it affects
All pharmacies, wholesalers, and other entities that handle xylazine, including independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies.
What you must do
Monitor the bill's progress and prepare for potential DEA registration and compliance obligations for xylazine handling.
Deadline
Not specified in the provided text; the bill is still in the legislative process.
Source: https://www.congress.gov/bill/119th-congress/house-bill/1266
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court - kff.org
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- Prisma Health Midlands to Pay $1 Million to Resolve Alleged Controlled Substance Act Violations - DEA.gov
- Utah opens applications for another medical cannabis license - mjbizdaily.com